Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

341305 Fasentin - CAS 392721-37-8 - Calbiochem

341305
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
341305-25MGCN Plastic ampoule 25 mg
Description
OverviewA cell-permeable oxobutananilide compound that is predicted to interact with Glut (Glucose Transporter) at an intracellular site based on a virtual docking study and shown to inhibit Glut-mediated cellular glucose uptake (50% and 80% inhibition of 2-deoxy-D-glucose uptake in Glut1- and Glut4-overexpressing L6 myoblasts, respectively, at 300 µM). Fas-resistant cell lines that are made Fas-responsive upon medium glucose deprivation are also shown to be sensitized by Fasentin to Fas-mediated cell death (ED50 = 35 µM in PPC-1 cultures), while cells that remain Fas-resistant upon glucose deprivation, e.g. DU145, are shown not to be sensitized by Fasentin to Fas-mediated death.
Catalogue Number341305
Brand Family Calbiochem®
Synonyms6094911, N-(4-Chloro-3-(trifluoromethyl)phenyl)-3-oxobutanamide, Glucose Transporter Inhibitor
References
ReferencesWood, T.E., et al. 2008. Mol. Cancer Ther. 7, 3546
Schimmer, A.D., et al. 2006. Cancer Res. 66, 2367.
Product Information
CAS number392721-37-8
FormOff-white solid
Hill FormulaC₁₁H₉ClF₃NO₂
Chemical formulaC₁₁H₉ClF₃NO₂
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥95% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -2°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
341305-25MGCN 04055977215649

Documentation

Fasentin - CAS 392721-37-8 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Fasentin - CAS 392721-37-8 - Calbiochem Certificates of Analysis

TitleLot Number
341305

References

Reference overview
Wood, T.E., et al. 2008. Mol. Cancer Ther. 7, 3546
Schimmer, A.D., et al. 2006. Cancer Res. 66, 2367.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision08-April-2011 RFH
Synonyms6094911, N-(4-Chloro-3-(trifluoromethyl)phenyl)-3-oxobutanamide, Glucose Transporter Inhibitor
DescriptionA cell-permeable oxobutananilide compound that is predicted to interact with Glut (Glucose Transporter) at an intracellular site based on a virtual docking study and shown to inhibit Glut-mediated cellular glucose uptake (50% and 80% inhibition of 2-deoxy-D-glucose uptake in Glut1- and Glut4-overexpressing L6 myoblasts, respectively, at 300 µM). Fas-resistant cell lines that are made Fas-responsive upon medium glucose deprivation are also shown to be sensitized by Fasentin to Fas-mediated cell death (ED50 = 35 µM in PPC-1 cultures), while cells that remain Fas-resistant upon glucose deprivation, e.g. DU145, are shown not to be sensitized by Fasentin to Fas-mediated death.
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number392721-37-8
Chemical formulaC₁₁H₉ClF₃NO₂
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (20 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -2°C.
Toxicity Standard Handling
ReferencesWood, T.E., et al. 2008. Mol. Cancer Ther. 7, 3546
Schimmer, A.D., et al. 2006. Cancer Res. 66, 2367.